Foresight (2005) ‘Brain Science Addiction and Drugs’, see www.foresight.com
2.
Gonzalez A , Nutt D J (2005) Gammahydroxybutyrate (GHB) abuse and dependency . Journal of Psychopharmacology19(2): 195–204
3.
Law F , Daglish M R C , Myles J S , Nutt D J (2004) The clinical use of buprenorphine in opiate addiction: evidence and practice . Acta Neuropsychiatrica16: 246–274
4.
Lingford-Hughes A , Nutt D (2003) Neurobiology of addiction and implications for treatment . Br J Psychiatry182: 97–100
5.
Lingford-Hughes A , Welch S , Nutt D J (2004) Evidence based guidelines for the pharmacological management of substance misuse, addiction and company-morbidity . Journal of Psychopharmacology18: 293–335
6.
Nutt D J (2005) Making sense of GABA-A receptor subtypes – is a new nomenclature needed?Journal of Psychopharmacology19(3): 219–220
7.
Nutt D J , Malizia A L (2001) New insights into the role of the GABA(A)benzodiazepine receptor in psychiatric disorder . Br J Psychiatry179: 390–396
8.
Potokar J , Nutt D J (1994) Anxiolytic potential of benzodiazepine receptor partial agonists . CNS Drugs1: 305–315
9.
Room R , Babor T , Rehm J (2005) Alcohol and public health . Lancet365(9458): 519–530
10.
Sundstrom-Paromaa I , Smith D H , Gong Q H , Sabado T N , Li X , Light A , Wiedmann M , Williams K , Smith S S (2002) Hormonally regulated a4b2d receptors are a target for ethanol . Nature Neuroscience5: 721–722
11.
Swanson C J , Bures M , Johnson M P , Linden A-M , Monn J A , Schoepp D D (2005) Metabotropic glutamate receptors as novel targets for anxiety and stress disorders . Nature Reviews Drug Discovery4: 131–144
